home / stock / huge / huge news


HUGE News and Press, FSD Pharma Inc. From 05/12/23

Stock Information

Company Name: FSD Pharma Inc.
Stock Symbol: HUGE
Market: NASDAQ
Website: fsdpharma.com

Menu

HUGE HUGE Quote HUGE Short HUGE News HUGE Articles HUGE Message Board
Get HUGE Alerts

News, Short Squeeze, Breakout and More Instantly...

HUGE - FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - FSD Pharma awarded CAD 2.81M in costs of arbitration in favor of former CEO lawsuit

2023-05-11 08:58:05 ET Biopharmaceutical company FSD Pharma ( NASDAQ: HUGE ) has been awarded about CAD2.81M in costs of arbitration by Justice Cunningham. The costs award particularizes the amount of FSD Pharma’s costs entitlement, which includes legal fees of CAD1.98M...

HUGE - FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has completed dosing the first cohort of patients ...

HUGE - FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - Sidoti's Micro-Cap Virtual May Conference

NEW YORK, NY / ACCESSWIRE / May 9, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events ...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that Zeeshan Saeed, ...

HUGE - FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...

HUGE - North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry

2023-04-18 08:45:06 ET Palm Beach, FL – April 18, 2023 – FinancialNewsMedia.com News Commentary – Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any symptoms of alcohol consumpt...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced completion of the fi...

Previous 10 Next 10